2015 ISAKOS Biennial Congress Paper #0

75% Survival Rate 15-Years After Arthroscopic Bone Marrow Stimulation For Osteochondral Lesions Of The Talus

Quinten G.H. Rikken, BSc., Amsterdam NETHERLANDS
Margot Aalders, BSc., Amsterdam NETHERLANDS
Jari Dahmen, MD, BSc, Amsterdam NETHERLANDS
Gino M. M. J. Kerkhoffs, MD, PhD, Prof., Amsterdam NETHERLANDS
Sjoerd A.S. Stufkens, MD, PhD, Amsterdam NETHERLANDS
Amsterdam UMC, Location AMC, Amsterdam, NETHERLANDS

FDA Status Not Applicable

Summary: 75% of patients who undergo arthroscopic BMS for OLT do not undergo revision surgery for their OLT at an average follow-up of 15 years. From this cohort of consecutive patients from a tertiary referral centre no prognostic demographic or lesion factors for procedure survival could be identified. The present study shows that survival of BMS for OLT is fair, even in patients with less favourable les

Abstract:

Purpose

The most common surgical treatment for osteochondral lesions of the talus (OLT) is arthroscopic bone marrow stimulation (BMS). Although clinical outcomes can be considered satisfactory up to mid- and long-term follow-up, there is a concern in the literature that BMS may eventually fail over time and there is a clear paucity in the literature in long-term survival data. It was therefore the primary aim of this study to assess the 10-year survival rate following arthroscopic BMS for OLT. The secondary aim was to assess possible prognostic baseline demographic and lesion factors for revision surgery.

Methods

All consecutive patients who underwent arthroscopic BMS for OLT with a minimum follow-up of 10-years were cross-sectionally included from a historic database of a tertiary academic referral centre. Patients were contacted and evaluated for the occurrence of revision surgery (i.e., reoperation of OLT or joint replacement/fusion after index surgery). The cumulative survival rate was evaluated and visualized using a Kaplan-Meier survival analysis for the primary outcome, namely the survival rate at 10 years follow-up, and at final follow-up. Additionally, the mean time to revision surgery was calculated. The secondary outcome concerned the evaluation of the following prognostic baseline factors on survival: primary or non-primary (i.e., previously failed surgical treatment) lesion, lesion size (<150mm2 vs. >150mm2), cystic lesion morphology (cystic vs. non-cystic lesion), and sex (male vs. female), and were analysed using a Cox proportional hazards model. P<0.05 was considered significant.

Results

182 patients were included for final follow-up at mean 15.0 ± 4.6 years after their index BMS procedure. 59% of patients are males, 35 ± 11.6 years at baseline, and 75% presented with a traumatic injury aetiology. Concerning lesion characteristics, 69% of patients presented with a large (>150mm2) lesion, 21% presented with a non-primary lesion, and 70% presented with a cystic lesion. Of the 182 patients, 42 patients underwent revision surgery at minimum 10-years follow-up, with a cumulative survival rate of 77% (95%-CI: 70% - 83%). At final follow-up, the cumulative survival rate was 72% (95%-CI: 65% - 78%) Average time to revision surgery was 4.3 ± 4.9 years. In terms of prognostic factors, the lesion size - HR: 0.8 [95%-CI: 0.4-1.7], P= 0.6), primary vs. non-primary OLT (HR: 0.6 [95%-CI: 0.3-1.3], P= 0.2), cystic lesion morphology (HR: 1.2 [95%-CI: 0.6-2.3], P= 0.7), and sex (male vs. female - HR: 0.6 [95%-CI: 0.3-1.1], P= 0.1) were not significantly associated with survival.

Conclusion

75% of patients who undergo arthroscopic BMS for OLT do not undergo revision surgery for their OLT at an average follow-up of 15 years. From this cohort of consecutive patients from a tertiary referral centre no prognostic demographic or lesion factors for procedure survival could be identified. The present study shows that survival of BMS for OLT is fair, even in patients with less favourable lesion characteristics.